AAAAAA
Results: 1-25/26
Authors:
Allorge, D
Harlow, J
Boulet, O
Hayhurst, GP
Chowdry, J
Roth, E
Crewe, K
Lo-Guidice, JM
Lhermitte, M
Broly, F
Tucker, GT
Ellis, SW
Citation: D. Allorge et al., In-vitro analysis of the contribution of CYP2D6.35 to ultrarapid metabolism, PHARMACOGEN, 11(8), 2001, pp. 739-741
Authors:
Johnson, TN
Tanner, MS
Taylor, CJ
Tucker, GT
Citation: Tn. Johnson et al., Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis, BR J CL PH, 51(5), 2001, pp. 451-460
Authors:
Rostami-Hodjegan, A
Tucker, GT
Citation: A. Rostami-hodjegan et Gt. Tucker, Journal impact factors: a 'bioequivalence' issue?, BR J CL PH, 51(2), 2001, pp. 111-117
Authors:
Hayhurst, GP
Harlow, J
Chowdry, J
Gross, E
Hilton, E
Lennard, MS
Tucker, GT
Ellis, SW
Citation: Gp. Hayhurst et al., Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6, BIOCHEM J, 355, 2001, pp. 373-379
Authors:
Tucker, GT
Citation: Gt. Tucker, Equivalence in disease states, EUR J DRUG, 25(1), 2000, pp. 71-71
Authors:
Forsyth, JT
Grunewald, RA
Rostami-Hodjegan, A
Lennard, MS
Sagar, HJ
Tucker, GT
Citation: Jt. Forsyth et al., Parkinson's disease and CYP1A2 activity, BR J CL PH, 50(4), 2000, pp. 303-309
Authors:
Ellis, SW
Hayhurst, GP
Lightfoot, T
Smith, G
Harlow, J
Rowland-Yeo, K
Larsson, C
Mahling, J
Lim, CK
Wolf, CR
Blackburn, MG
Lennard, MS
Tucker, GT
Citation: Sw. Ellis et al., Evidence that serine 304 is not a key ligand-binding residue in the activesite of cytochrome P450 2D6, BIOCHEM J, 345, 2000, pp. 565-571
Authors:
Tucker, GT
Citation: Gt. Tucker, Advances in understanding drug metabolism and its contribution to variability in patient response, THER DRUG M, 22(1), 2000, pp. 110-113
Authors:
Tucker, GT
Citation: Gt. Tucker, Chiral switches, LANCET, 355(9209), 2000, pp. 1085-1087
Authors:
Coleman, T
Spellman, EF
Rostami-Hodjegan, A
Lennard, MS
Tucker, GT
Citation: T. Coleman et al., The 1 '-hydroxylation of rac-bufuralol by rat brain microsomes, DRUG META D, 28(9), 2000, pp. 1094-1099
Authors:
Lightfoot, T
Ellis, SW
Mahling, J
Ackland, MJ
Blaney, FE
Bijloo, GJ
De Groot, MJ
Vermeulen, NPE
Blackburn, GM
Lennard, MS
Tucker, GT
Citation: T. Lightfoot et al., Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling, XENOBIOTICA, 30(3), 2000, pp. 219-233
Authors:
Johnson, TN
Tanner, MS
Tucker, GT
Citation: Tn. Johnson et al., A comparison of the ontogeny of enterocytic and hepatic cytochromes P450 3A in the rat, BIOCH PHARM, 60(11), 2000, pp. 1601-1610
Authors:
Siy, HP
Herbsleb, JD
Mockus, A
Krishnan, M
Tucker, GT
Citation: Hp. Siy et al., Making the software factory work: Lessons from a decade of experience, SEVENTH INTERNATIONAL SOFTWARE METRICS SYMPOSIUM - METRICS 2001, PROCEEDINGS, 2000, pp. 317-326
Authors:
Rostami-Hodjegan, A
Kroemer, HK
Tucker, GT
Citation: A. Rostami-hodjegan et al., In-vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity, PHARMACOGEN, 9(3), 1999, pp. 277-286
Authors:
Schulz-Utermoehl, T
Bennett, AJ
Ellis, SW
Tucker, GT
Boobis, AR
Edwards, RJ
Citation: T. Schulz-utermoehl et al., Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression, PHARMACOGEN, 9(3), 1999, pp. 357-366
Authors:
Marez-Allorge, D
Ellis, SW
Lo Guidice, JM
Tucker, GT
Broly, F
Citation: D. Marez-allorge et al., A rare G(2061) insertion affecting the open reading frame of CYP2D6 and responsible for the poor metabolizer phenotype, PHARMACOGEN, 9(3), 1999, pp. 393-396
Authors:
Manap, RA
Wright, CE
Gregory, A
Rostami-Hodjegan, A
Meller, ST
Kelm, GR
Lennard, MS
Tucker, GT
Morice, AH
Citation: Ra. Manap et al., The antitussive effect of dextromethorphan in relation to CYP2D6 activity, BR J CL PH, 48(3), 1999, pp. 382-387
Authors:
Rostami-Hodjegan, A
Wolff, K
Hay, AWM
Raistrick, D
Calvert, R
Tucker, GT
Citation: A. Rostami-hodjegan et al., Population pharmacokinetics of methadone in opiate users: characterizationof time-dependent changes, BR J CL PH, 48(1), 1999, pp. 43-52
Authors:
Rostami-Hodjegan, A
Funck-Brentano, C
Kroemer, HK
Tucker, GT
Citation: A. Rostami-hodjegan et al., In vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity, BR J CL PH, 47(5), 1999, pp. 577-578
Authors:
Ghahramani, P
Jackson, PR
Tucker, GT
Citation: P. Ghahramani et al., Fraction of dose of drug converted to a metabolite when both compete for metabolism by the same enzyme, BR J CL PH, 47(5), 1999, pp. 578-578
Authors:
Forsyth, J
Grunewald, RA
Lennard, MS
Rostami-Hodjegan, A
Sagar, HJ
Tucker, GT
Citation: J. Forsyth et al., Altered caffeine metabolism in patients with Parkinson's disease, BR J CL PH, 47(5), 1999, pp. 579-580
Authors:
Abdul-Manap, R
Wright, CE
Rostami-Hodjegan, A
Meller, S
Lennard, MS
Morice, AH
Tucker, GT
Citation: R. Abdul-manap et al., Cytochrome P450 2D6 (CYP2D6) activity in relation to the antitussive effect of dextromethorphan, BR J CL PH, 47(5), 1999, pp. 586-587
Authors:
Rostami-Hodjegan, A
Forsyth, J
Grunewald, RA
Lennard, MS
Sagar, HJ
Tucker, GT
Citation: A. Rostami-hodjegan et al., The paraxanthine caffeine ratio in saliva as a marker of CYP1A2 activity, BR J CL PH, 47(5), 1999, pp. 587-588
Authors:
Segall, MD
Payne, MC
Ellis, SW
Tucker, GT
Eddershaw, PJ
Citation: Md. Segall et al., First principles investigation of singly reduced cytochrome P450, XENOBIOTICA, 29(6), 1999, pp. 561-571
Authors:
Marsh, JCW
Chowdry, J
Parry-Jones, N
Ellis, SW
Muir, KR
Gordon-Smith, EC
Tucker, GT
Citation: Jcw. Marsh et al., Study of the association between cytochromes P450 2D6 and 2E1 genotypes and the risk of drug and chemical induced idiosyncratic aplastic anaemia, BR J HAEM, 104(2), 1999, pp. 266-270